绿康生化(002868) - 2025 Q2 - 季度业绩预告

Lvkang Bio 2025 Semi-Annual Performance Forecast Current Period Performance Forecast The company expects to record a net loss in the first half of 2025, with the loss amount projected to narrow compared to the same period last year, as net profit attributable to shareholders is estimated to be a loss of RMB 50 million to RMB 65 million, representing a year-on-year reduction in loss of 25.35% to 42.58% Performance Forecast Summary | Item | Current Period (2025 H1 Est.) | Prior Period (2024 H1) | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Loss: RMB 50 million – RMB 65 million | Loss: RMB 87.0785 million | | | Year-on-year reduction in loss: 25.35% – 42.58% | | | Net Profit Attributable to Shareholders After Non-Recurring Items | Loss: RMB 68 million – RMB 80 million | Loss: RMB 104.3645 million | | | Year-on-year reduction in loss: 23.35% – 34.84% | | | Basic Earnings Per Share | Loss: RMB 0.32/share – RMB 0.42/share | Loss: RMB 0.56/share | Communication with Accounting Firm This performance forecast has not been pre-audited by a certified public accountant, and its accuracy awaits final audit confirmation - This performance forecast has not been pre-audited by a certified public accountant[3] Explanation of Performance Changes The company's loss narrowed in the current period, primarily due to increased gross profit margin in the veterinary drug business and reduced inventory impairment losses - Gross profit margin for the veterinary drug business increased year-on-year due to sales growth[4] - The company strengthened inventory management, reduced inventory scale, and consequently decreased inventory impairment losses compared to the same period last year[4] Risk Warning and Other Related Information The company faces severe delisting risks due to negative net assets and an *ST designation, with potential termination of listing if 2025 financial indicators again trigger relevant regulations - The company's net assets at the end of 2024 were negative, and are expected to remain negative at the end of the first half of 2025[6] - The company's stock has been subject to a "delisting risk warning" (*ST) since April 30, 2025, with a daily price fluctuation limit of 5%[6] - If the company's audited financial indicators for the 2025 fiscal year again trigger delisting clauses, the company's stock will be terminated from listing[6] - This performance forecast is a preliminary calculation by the company's finance department, and the final data will be subject to the 2025 semi-annual report[6]